GaryKSchwartzMD

Professor of Medicine Chief, Division of Hematology/Oncology Columbia University Irving Medical Center Deputy Director, Herbert Irving Comprehensive Cancer Center

Join to view full profile

Dr. Schwartz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Schwartz's full profile

Already have an account?

Office
10900 Euclid Ave.
Cleveland, OH 44106
Phone+1 216-368-1994
Is this information wrong?

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1986 - 1988
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1985 - 1986
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1983 - 1984
Albany Medical CollegeClass of 1983

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1984 - 2025
OH State Medical License 2023 - 2025
NJ State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 1995 Apr 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors Start of enrollment: 1997 Jul 01
Completed
Phase 1
Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Feb 01
Completed
Phase 1
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors Start of enrollment: 1999 Jul 01
Completed
Phase 1
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer Start of enrollment: 2000 Feb 01
Completed
Phase 2
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel Start of enrollment: 2000 Jul 01
Completed
Phase 2
LY293111 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Jun 01
Completed
Phase 1
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Sep 01
Completed
Phase 1
Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Oct 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2002 May 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Apr 01
Completed
Phase 1
UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 2002 Jul 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Jul 01
Completed
Phase 1
Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer Start of enrollment: 2002 Aug 01
Completed
Phase 1
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2003 Oct 01
Completed
Phase 2
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 Feb 01
Completed
Phase 1
Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2004 Mar 01
Completed
Phase 1
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 Mar 01
Completed
Phase 1
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
Completed
Phase 2
PTC299 for Treatment of Advanced Cancer Start of enrollment: 2008 Jul 03
Terminated
Phase 1
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Start of enrollment: 2009 Nov 01
Completed
Phase 2
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Start of enrollment: 2010 Jun 01
Completed
Phase 1, Phase 2
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Start of enrollment: 2010 Sep 23
Completed
Phase 2
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Start of enrollment: 2010 Nov 01
Completed
Phase 2
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Start of enrollment: 2011 Dec 20
Completed
Phase 1
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors Start of enrollment: 2012 Nov 27
Terminated
Phase 1, Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Start of enrollment: 2013 Aug 01
Terminated
Phase 1, Phase 2
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Start of enrollment: 2013 Nov 01
Terminated
Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Start of enrollment: 2013 Oct 23
Completed
Phase 2
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Start of enrollment: 2014 Mar 21
Completed
Phase 3
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Emiloju, O., Yin, J., Koubek, E., Reid, J., Borad, M., Lou, Y., Seetharam, M., Edelman, M., Sausville, E., Jiang, Y., Kaseb, A., Posey, J., Davis, S., Gores, G., Rober...> ;Investigational New Drugs. 2024 Feb 1
Desmoid Tumors: Current Perspective and Treatment.
Agarwal, N., Mangla, A., Schwartz, G.> ;Current Treatment Options in Oncology. 2024 Feb 1
Evaluating disruptions in melanoma diagnosis resulting from the COVID-19 pandemic from a community-based perspective.
Uriel Kim, Richard S Hoehn, Jennifer Cullen, Jeremy S Bordeaux, Ankit Mangla, Bryan T Carroll, Schwartz, G.> ;Journal of the American Academy of Dermatology. 2024 Jan 1
A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
Alan L Ho, Nathan R Foster, Shyamprasad Deraje Vasudeva, Nora Katabi, Cristina R Antonescu, Gary P Frenette, David G Pfister, Charles Erlichman, Schwartz, G.> ;Cancer. 2024 Mar 1
2 citations
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors.
César Serrano, Sara Rothschild, Guillermo Villacampa, Michael C Heinrich, Suzanne George, Jean-Yves Blay, Jason K Sicklick, Sameer Rastogi, Robin L Jones, Piotr Rutkow...> ;Nature Medicine. 2023 Nov 1
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA).
Wei, A., Chen, L., Orloff, M., Ariyan, C., Asgari, M., Barker, C., Buchbinder, E., Chandra, S., Couts, K., Frumovitz, M., Futreal, A., Gershenwald, J., Hanna, E., Izar...> ;Pigment Cell & Melanoma Research. 2023 Nov 1
3 citations
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.
Elena Garralda, Alison M Schram, Philippe L Bedard, Gary K Schwartz, Eunice Yuen, Samuel C McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaoji...> ;The Oncologist. 2024 Jan 5
Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term Safety.
Gary K Schwartz> ;Journal of Clinical Oncology. 2023 Feb 10
15 citations
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Mrinal M Gounder, Todd M Bauer, Gary K Schwartz, Patricia LoRusso, Prasanna Kumar, Ben Tao, Ying Hong, Parul Patel, Yasong Lu, Arnaud Lesegretain, Vijaya G Tirunagaru,...> ;Journal of Clinical Oncology. 2023 Mar 20
Flashback Foreword: Adjuvant Interferon α-2b for High-Risk Melanoma.
Gary K Schwartz> ;Journal of Clinical Oncology. 2023 Jan 20
7 citations
Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens.
Yiping Wang, Joy Linyue Fan, Johannes C Melms, Amit Dipak Amin, Yohanna Georgis, Irving Barrera, Patricia Ho, Somnath Tagore, Gabriel Abril-Rodríguez, Siyu He, Yinuo J...> ;Nature Genetics. 2023 Jan 1
20 citations
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
Vikas, P., Bakouny, Z., Labaki, C., Grover, P., Awosika, J., Gulati, S., Hsu, C., Alimohamed, S., Bashir, B., Berg, S., Bilen, M., Bowles, D., Castellano, C., Desai, A...> ;JAMA Oncology. 2023 Jan 1
1 citations
A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma.
Matthew Ingham, Shing Lee, Brian A Van Tine, Edwin Choy, Jay Oza, Liner Ge, Peter Oppelt, Gregory Cote, Brian Corgiat, Naomi Sender, Sarah Sta Ana, Lavan Panchalingam,...> ;Clinical Cancer Research. 2023 Mar 14
1 citations
Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry.
Nadia Mezghani, Alexandria Yao, Daria Vasilyeva, Nicole Kaplan, Austin Shackelford, Angela Yoon, Elizabeth Phillipone, Sunil Dubey, Gary K Schwartz, Alison M Taylor, F...> ;Clinical Cancer Research. 2023 Mar 1
Interest in genetic testing and risk-reducing behavioral changes: results from a community health assessment in New York City.
Sarah M Lima, Meaghan Nazareth, Karen M Schmitt, Andria Reyes, Elaine Fleck, Gary K Schwartz, Mary Beth Terry, Grace C Hillyer> ;Journal of Community Genetics. 2022 Dec 1
6 citations
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastat...
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, Mark Agulnik, Mohammed M Milhem, Suzanne George, Robin L Jones, Bartosz Chmielowski, Brian A Van Tine, Hussein Tawbi,...> ;European Journal of Cancer. 2022 Nov 1
3 citations
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
Wagner, M., Hennessy, C., Beeghly, A., French, B., Shah, D., Croessmann, S., Vilar-Compte, D., Ruiz-Garcia, E., Ingham, M., Schwartz, G., Painter, C., Chugh, R., Feche...> ;Cancers. 2022 Sep 5
1 citations
Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine.
Gary K Schwartz> ;Journal of Clinical Oncology. 2022 Dec 1
14 citations
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Mrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz ...> ;Journal of Clinical Oncology. 2022 Aug 1
13 citations
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
Alan L Ho, Nathan R Foster, Alex J Zoroufy, Jordan D Campbell, Francis Worden, Katharine Price, Douglas Adkins, Daniel W Bowles, Hyunseok Kang, Barbara Burtness, Eric ...> ;Journal of Clinical Oncology. 2022 Dec 20
46 citations
Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
Jana Biermann, Johannes C Melms, Amit Dipak Amin, Yiping Wang, Lindsay A Caprio, Alcida Karz, Somnath Tagore, Irving Barrera, Miguel A Ibarra-Arellano, Massimo Andreat...> ;Cell. 2022 Jul 7
1 citations
CDK4/6 Inhibition With Anti-PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD-1 Alone.
Tristan Lee, Shaelyn Choi, Ladan Fazlollahi, Michael J Rasiej, Gary K Schwartz, Matthew Ingham, Sminu Bose> ;JCO Precision Oncology. 2022 Jul 1
50 citations
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.
Mrinal M Gounder, Narasimhan P Agaram, Sally E Trabucco, Victoria Robinson, Richard A Ferraro, Sherri Z Millis, Anita Krishnan, Jessica Lee, Steven Attia, Wassim Abida...> ;Nature Communications. 2022 Jun 15
19 citations
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma.
Mrinal M Gounder, Evan Rosenbaum, Nian Wu, Mark A Dickson, Tahir N Sheikh, Sandra P D'Angelo, Ping Chi, Mary Lou Keohan, Joseph P Erinjeri, Cristina R Antonescu, Naras...> ;Clinical Cancer Research. 2022 Apr 14
12 citations
Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment through Macrophage Migration Inhibitory Factor.
Grazia Ambrosini, Alex J Rai, Richard D Carvajal, Gary K Schwartz> ;Molecular Cancer Research. 2022 Apr 1
Join now to see all

Journal Articles

Sorafenib for Advanced and Refractory Desmoid Tumors
Gary Schwartz, MD, The New England Journal of Medicine

Press Mentions

Sequencing Matters – Combination Dabrafenib/Trametinib Versus Nivolumab/Ipilimumab for Advanced BRAF-Mutant Melanoma: The DREAMseq TrialMarch 9th, 2023
Angiosarcoma Research Project Produces Windfall of Druggable InsightsApril 8th, 2020
Six Columbia Cancer Researchers Receive Seed Funding from VelocityJuly 15th, 2019
Join now to see all

Grant Support

P2 - Developing New Strategies For Targeting Pdgfr/Pi3k/Akt Pathways In SarcomaNational Cancer Institute2010–2011
Developing New Strategies For Targeting Mtor And Igf-1r/Pi3k/Akt Pathways In SarcNational Cancer Institute2009–2011
Translational Research Studies In Clinical Trials Of Novel Therapeutics For SarcoNational Cancer Institute2010
Phase II Study Of Imatinib Mesylate In Patients With Inoperable MelanomaFood And Drug Administration2008–2010
Mskcc Clinical Oncology Research Career Development ProgramNational Cancer Institute2006–2010
Laboratory &Clinical Develpmt Of Cell Cycle Active Agents In The Treatmt Of STSNational Cancer Institute2006–2010
Clinical Trials Of Flavopiridol With ChemotherapyNational Cancer Institute2001–2008
Phase I Trial Of Safingol And CisplatinNational Cancer Institute2005–2006
Genetics Of Low Renin HypertensionNational Center For Research Resources2005
Mentoring For New Cancer TherapeauticsNational Cancer Institute2001–2005
Drg1: A Novel Molecular Target For Cancer TherapyNational Cancer Institute2002
Protein Kinase C--A Novel Target For Cancer TherapyNational Cancer Institute1996–2000
Core--BioenergeticsNational Heart, Lung, And Blood Institute1998